Oruka Therapeutics, Inc.
ORKA
Rangering i aksjer
#3302
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses... Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Aksjekurs
$80.01
Sist synkronisert: 2026-10-21
Markedsverdi
$5.30B
Endring (1 dag)
1.16%
Endring (1 år)
200.21%
Land
US
Handel Oruka Therapeutics, Inc. (ORKA)
Kategori
Healthcare
Historikk for aksjesplitt for Oruka Therapeutics, Inc. (ORKA)
Aksjen Oruka Therapeutics, Inc. (symbol: ORKA) har gjennomgått totalt 0 aksjesplitt.
Den nyeste splittelsen skjedde Oct 22, 2026.
Én ORKA-aksje kjøpt før Oct 22, 2026 tilsvarer i dag 0 ORKA-aksjer.
Den nyeste splittelsen skjedde Oct 22, 2026.
Én ORKA-aksje kjøpt før Oct 22, 2026 tilsvarer i dag 0 ORKA-aksjer.
Liste over aksjesplitt
| År | Splitt | Multiplikator | Kumulativ multiplikator |
|---|---|---|---|
| Ikke nok data for de angitte datoene. | |||
Aksjesplitt for lignende selskaper eller konkurrenter
| Selskap | Antall aksjesplitt | Kumulativ multiplikator | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
NL
|
|
| 0 | - |
CH
|